Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
5-Fluoro-2-deoxycytidine | FdCyd|RO-5-1090 | 5-Fluoro-2-deoxycytidine (FdCyd) is a fluorinated pyrimidine analogue that is metabolized to 5-fluorouracil (5-FU) intercellularly, which is cytotoxic (PMID: 17899082). | ||
Tetrahydrouridine | THU | Tetrahydrouridine is a synthetic pyrimidine analogue that inhibits deoxycytidine monophosphate (dCMP) deaminase, which in turn inhibits cell proliferation (PMID: 22616006, PMID: 32314030). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00978250 | Phase II | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | Completed | USA | 0 |
NCT01534598 | Phase I | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | FdCyd and THU for Advanced Solid Tumors | Completed | USA | 0 |